R Squared Ltd Invests $442,000 in Thermo Fisher Scientific Inc. (NYSE:TMO)

R Squared Ltd acquired a new stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 850 shares of the medical research company’s stock, valued at approximately $442,000.

A number of other large investors have also recently modified their holdings of the business. Driehaus Capital Management LLC lifted its stake in Thermo Fisher Scientific by 75.0% in the 2nd quarter. Driehaus Capital Management LLC now owns 1,524 shares of the medical research company’s stock valued at $843,000 after purchasing an additional 653 shares during the last quarter. Quarry LP boosted its holdings in shares of Thermo Fisher Scientific by 86.2% during the 2nd quarter. Quarry LP now owns 121 shares of the medical research company’s stock valued at $67,000 after acquiring an additional 56 shares in the last quarter. EP Wealth Advisors LLC increased its holdings in Thermo Fisher Scientific by 5.8% in the 2nd quarter. EP Wealth Advisors LLC now owns 14,991 shares of the medical research company’s stock worth $8,290,000 after purchasing an additional 816 shares in the last quarter. Pathway Financial Advisers LLC raised its position in Thermo Fisher Scientific by 2.3% in the second quarter. Pathway Financial Advisers LLC now owns 1,450 shares of the medical research company’s stock valued at $783,000 after purchasing an additional 33 shares during the last quarter. Finally, Advisory Alpha LLC grew its holdings in shares of Thermo Fisher Scientific by 34.7% during the second quarter. Advisory Alpha LLC now owns 1,049 shares of the medical research company’s stock worth $580,000 after purchasing an additional 270 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Thermo Fisher Scientific Stock Up 0.1 %

Thermo Fisher Scientific stock opened at $584.38 on Wednesday. Thermo Fisher Scientific Inc. has a fifty-two week low of $493.30 and a fifty-two week high of $627.88. The firm’s 50-day simple moving average is $535.24 and its 200 day simple moving average is $570.10. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.26 and a current ratio of 1.63. The stock has a market cap of $223.52 billion, a PE ratio of 36.64, a price-to-earnings-growth ratio of 3.82 and a beta of 0.76.

Thermo Fisher Scientific Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, January 15th. Shareholders of record on Friday, December 13th were given a $0.39 dividend. The ex-dividend date was Friday, December 13th. This represents a $1.56 annualized dividend and a yield of 0.27%. Thermo Fisher Scientific’s dividend payout ratio is currently 9.78%.

Thermo Fisher Scientific declared that its Board of Directors has approved a share repurchase plan on Friday, November 15th that permits the company to buyback $4.00 billion in outstanding shares. This buyback authorization permits the medical research company to reacquire up to 2% of its shares through open market purchases. Shares buyback plans are often a sign that the company’s board of directors believes its shares are undervalued.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on TMO shares. TD Cowen lifted their target price on shares of Thermo Fisher Scientific from $656.00 to $686.00 in a research report on Tuesday, October 22nd. Stifel Nicolaus decreased their price objective on Thermo Fisher Scientific from $680.00 to $665.00 and set a “buy” rating for the company in a report on Thursday, October 24th. Royal Bank of Canada reduced their price target on Thermo Fisher Scientific from $767.00 to $718.00 and set an “outperform” rating on the stock in a research report on Thursday, October 24th. Robert W. Baird lowered their price objective on Thermo Fisher Scientific from $632.00 to $622.00 and set an “outperform” rating for the company in a research report on Thursday, October 24th. Finally, Redburn Atlantic started coverage on Thermo Fisher Scientific in a report on Monday, October 14th. They issued a “buy” rating and a $680.00 target price on the stock. Four analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Thermo Fisher Scientific presently has an average rating of “Moderate Buy” and a consensus price target of $648.95.

Insider Transactions at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $530.26, for a total value of $5,302,600.00. Following the transaction, the chief executive officer now owns 111,192 shares in the company, valued at approximately $58,960,669.92. This represents a 8.25 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold 34,850 shares of company stock worth $19,123,197 in the last ninety days. Company insiders own 0.34% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.